Review
Open access
Oct 2026
Beta-cell replacement for type 1 diabetes: integrating cell products, engraftment and immune protection
No platform has yet combined durable function, immune control, scalable production and acceptable long-term safety in type 1 diabetes, and this review examines donor islets, stem-cell-derived products and islet-like organoids as parts of one treatment system.
Lan Chen, Xin-Hao Hu, Chen Zheng et al.
· Frontiers in Endocrinology · 0 citations